tbuckley/cabot-search huggingface dataset:
Intranasal priming induces local lung-resident B cell populations that secrete protective mucosal antiviral IgA
Authors: Ji Eun Oh, Eric Song, Miyu Moriyama, Patrick Wong, Sophia Zhang, Ruoyi Jiang, Shirin Strohmeier, Steven H. Kleinstein, Florian Krammer, Akiko Iwasaki
Journal: Science Immunology (2021)

Antibodies secreted at the mucosal surface play an integral role in immune defense by serving to neutralize the pathogen and promote its elimination at the site of entry. Secretory immunoglobulin A (IgA) is a predominant Ig isotype at mucosal surfaces whose epithelial cells express polymeric Ig receptor capable of transporting dimeric IgA to the lumen. Although the role of IgA in intestinal mucosa has been extensively studied, the cell types responsible for secreting the IgA that protects the host against pathogens in the lower respiratory tract are less clear. Here, using a mouse model of influenza virus infection, we demonstrate that intranasal, but not systemic, immunization induces local IgA secretion in the bronchoalveolar space. Using single-cell RNA sequencing, we found a heterogeneous population of IgA-expressing cells within the respiratory mucosa, including tissue-resident memory B cells, plasmablasts, and plasma cells. IgA-secreting cell establishment within the lung required CXCR3. An intranasally administered protein-based vaccine also led to the establishment of IgA-secreting cells in the lung, but not when given intramuscularly or intraperitoneally. Last, local IgA secretion correlated with superior protection against secondary challenge with homologous and heterologous virus infection than circulating antibodies alone. These results provide key insights into establishment of protective immunity in the lung based on tissue-resident IgA-secreting B cells and inform vaccine strategies designed to elicit highly effective immune protection against respiratory virus infections.
Corrigendum to “Co-delivery of HIF1α siRNA and gemcitabine via biocompatible lipid-polymer hybrid nanoparticles for effective treatment of pancreatic cancer” [Biomaterials 46 (2015) 13–25]
Authors: Xiao Zhao, Feng Li, Yiye Li, Hai Wang, He Ren, Jing Chen, Guangjun Nie, Jihui Hao
Journal: Biomaterials (2021)
Smartphone-based digital phenotyping for dry eye toward P4 medicine: a crowdsourced cross-sectional study
Authors: Takenori Inomata, Masahiro Nakamura, Jaemyoung Sung, Akie Midorikawa-Inomata, Masao Iwagami, Kenta Fujio, Yasutsugu Akasaki, Yuichi Okumura, Keiichi Fujimoto, Atsuko Eguchi, Maria Miura, Ken Nagino, Hurramhon Shokirova, Jun Zhu, Mizu Kuwahara, Kunihiko Hirosawa, Reza Dana, Akira Murakami
Journal: npj Digital Medicine (2021)

Multidimensional integrative data analysis of digital phenotyping is crucial for elucidating the pathologies of multifactorial and heterogeneous diseases, such as the dry eye (DE). This crowdsourced cross-sectional study explored a novel smartphone-based digital phenotyping strategy to stratify and visualize the heterogenous DE symptoms into distinct subgroups. Multidimensional integrative data were collected from 3,593 participants between November 2016 and September 2019. Dimension reduction via Uniform Manifold Approximation and Projection stratified the collected data into seven clusters of symptomatic DE. Symptom profiles and risk factors in each cluster were identified by hierarchical heatmaps and multivariate logistic regressions. Stratified DE subgroups were visualized by chord diagrams, co-occurrence networks, and Circos plot analyses to improve interpretability. Maximum blink interval was reduced in clusters 1, 2, and 5 compared to non-symptomatic DE. Clusters 1 and 5 had severe DE symptoms. A data-driven multidimensional analysis with digital phenotyping may establish predictive, preventive, personalized, and participatory medicine.
153P Safety/tolerability and antitumor activity of sitravatinib plus tislelizumab (TIS) in patients with advanced platinum-resistant ovarian cancer (PROC)
Authors: J.C. Goh, J. Coward, B. Gao, I. Pires Da Silva, M. Voskoboynik, D. Day, A. Body, H.K. Gan, X. Li, J. Sun, C. Fei, L. Yang, M. Millward
Journal: Annals of Oncology (2021)
168TiP KEYNOTE-A86: Phase III, randomized, open-label study of first-line subcutaneous (SC) vs intravenous (IV) pembrolizumab with platinum doublet chemotherapy in metastatic squamous or nonsquamous non-small cell lung cancer (NSCLC)
Authors: B. Halmos, P. Cobb, M.L. Johnson, L. Jain, S.J. Kim, S. Saraf, M. Lala, T. Kurata
Journal: Annals of Oncology (2021)
Re: ‘Seven versus 14-days course of antibiotics for the treatment of bloodstream infections by Enterobacterales’ by Molina et al.
Authors: Aoi Tokimatsu, Teppei Mikami, Midori Yamada, Shoko Kamiwatari, Noriko Furuita, Yuki Kataoka
Journal: Clinical Microbiology and Infection (2021)
Hypofibrinogenemia with preserved hemostasis and protection from thrombosis in mice with an <i>Fga</i> truncation mutation
Authors: Woosuk S. Hur, David S. Paul, Emma G. Bouck, Oscar A. Negrón, Jean-Marie Mwiza, Lauren G. Poole, Holly M. Cline-Fedewa, Emily G. Clark, Lih Jiin Juang, Jerry Leung, Christian J. Kastrup, Tatiana P. Ugarova, Alisa S. Wolberg, James P. Luyendyk, Wolfgang Bergmeier, Matthew J. Flick
Journal: Blood (2021)
Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab
Authors: Ana-Marija Grisic, Wenyuan Xiong, Lénaïg Tanneau, Siv Jönsson, Lena E. Friberg, Mats O. Karlsson, Haiqing Dai, Jenny Zheng, Pascal Girard, Akash Khandelwal
Journal: Clinical Cancer Research (2021)

Abstract Purpose: Empirical time-varying clearance models have been reported for several immune checkpoint inhibitors, including avelumab (anti–programmed death ligand 1). To investigate the exposure-response relationship for avelumab, we explored semimechanistic pharmacokinetic (PK)–tumor growth dynamics (TGD) models. Patients and Methods: Plasma PK data were pooled from three phase I and II trials (JAVELIN Merkel 200, JAVELIN Solid Tumor, and JAVELIN Solid Tumor JPN); tumor size (TS) data were collected from patients with metastatic Merkel cell carcinoma (mMCC) enrolled in JAVELIN Merkel 200. A PK model was developed first, followed by TGD modeling to investigate interactions between avelumab exposure and TGD. A PK-TGD feedback loop was evaluated with simultaneous fitting of the PK and TGD models. Results: In total, 1,835 PK observations and 338 TS observations were collected from 147 patients. In the final PK-TGD model, which included the bidirectional relationship between PK and TGD, avelumab PK was described by a two-compartment model with a positive association between clearance and longitudinal TS, with no additional empirical time-varying clearance identified. TGD was described by first-order tumor growth/shrinkage rates, with the tumor shrinkage rate decreasing exponentially over time; the exponential time-decay constant decreased with increasing drug concentration, representing the treatment effect through tumor shrinkage inhibition. Conclusions: We developed a TGD model that mechanistically captures the prevention of loss of antitumor immunity (i.e., T-cell suppression in the tumor microenvironment) by avelumab, and a bidirectional interaction between PK and TGD in patients with mMCC treated with avelumab, thus mechanistically describing previously reported time variance of avelumab elimination.
37P PD-L1 on the endothelium of micrangium inside tumor: A novel predictor for the efficacy of anti-angiogenesis (anlotinib) plus anti-PD-L1 (TQ-B2450)?
Authors: L. Ma, C. Zhang, B. Han, T. Chu, Q. Wang, Y. Cheng, Y. Li
Journal: Annals of Oncology (2021)
More treatment but no less depression: The treatment-prevalence paradox
Authors: Johan Ormel, Steven D. Hollon, Ronald C. Kessler, Pim Cuijpers, Scott M. Monroe
Journal: Clinical Psychology Review (2021)

Treatments for depression have improved, and their availability has markedly increased since the 1980s. Mysteriously the general population prevalence of depression has not decreased. This "treatment-prevalence paradox" (TPP) raises fundamental questions about the diagnosis and treatment of depression. We propose and evaluate seven explanations for the TPP. First, two explanations assume that improved and more widely available treatments have reduced prevalence, but that the reduction has been offset by an increase in: 1) misdiagnosing distress as depression, yielding more "false positive" diagnoses; or 2) an actual increase in depression incidence. Second, the remaining five explanations assume prevalence has not decreased, but suggest that: 3) treatments are less efficacious and 4) less enduring than the literature suggests; 5) trial efficacy doesn't generalize to real-world settings; 6) population-level treatment impact differs for chronic-recurrent versus non-recurrent cases; and 7) treatments have some iatrogenic consequences. Any of these seven explanations could undermine treatment impact on prevalence, thereby helping to explain the TPP. Our analysis reveals that there is little evidence that incidence or prevalence have increased as a result of error or fact (Explanations 1 and 2), and strong evidence that (a) the published literature overestimates short- and long-term treatment efficacy, (b) treatments are considerably less effective as deployed in "real world" settings, and (c) treatment impact differs substantially for chronic-recurrent cases relative to non-recurrent cases. Collectively, these a-c explanations likely account for most of the TPP. Lastly, little research exists on iatrogenic effects of current treatments (Explanation 7), but further exploration is critical.
Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)
Authors: Daniel Rivera, Tapan M. Kadia, Guillermo Montalban-Bravo, Stefan Faderl, Koji Sasaki, Nicholas J. Short, Naval Daver, Courtney D. DiNardo, Lucia Masarova, Alessandra Ferrajoli, Elias J. Jabbour, Gautham Borthakur, Hind Al Azzawi, Marina Konopleva, Guillermo Garcia-Manero, Michael Andreeff, Hagop Kantarjian, Farhad Ravandi, Yesid Alvarado
Journal: Blood (2021)
Subclinical Electrographic Seizures in the Newborn—Is More Treatment Better?
Authors: Martin Offringa, Brian T. Kalish
Journal: JAMA Network Open (2021)

Rod W. Hunt, PhD; Helen G. Liley, MBChB; Deepika Wagh, MBBS; Rachel Schembri, PhD; Katherine J. Lee, PhD; Andrew D. Shearman, MClnSci; Samantha Francis-Pester, MBioethics; Koert deWaal, PhD; Jeanie Y. L. Cheong, MD; Monika Olischar, MD; Nadia Badawi, PhD; Flora Y. Wong, PhD; David A. Osborn, PhD; Victor Samuel Rajadurai, MD; Peter A. Dargaville, MD; Bevan Headley, MPhil; Ian Wright, PhD; Paul B. Colditz, PhD; Newborn Electrographic Seizure Trial Investigators; Susan E Jacobs; Connie Wong; Emma Yeomans; Kristy Elsayed; Judith Macey; Jan Stewart; Karen Simmer; Yen Kok; Ross Black; Lisa McKeown; Nicky Roberts; Nirmal K Visruthan; Rowena Dela Puerta; Stacey Worthington
171P An unwelcome guest: P. gingivalis intratumoral infection and immune evasion in gastric cancer
Authors: I.N. Retamal, M. Muñoz Medel, M. Cáceres, K. Cereceda, F. Villarroel-Espíndola, P. Manque, A. Berkovits, J.A. Ríos, B. García-Bloj, M.P. Rodríguez, A.H. Corvalán, G.I. Owen, R. Armisén, M. Garrido, A. Chaparro
Journal: Annals of Oncology (2021)
AAV capsid variants with brain-wide transgene expression and decreased liver targeting after intravenous delivery in mouse and marmoset
Authors: David Goertsen, Nicholas C. Flytzanis, Nick Goeden, Miguel R. Chuapoco, Alexander Cummins, Yijing Chen, Yingying Fan, Qiangge Zhang, Jitendra Sharma, Yangyang Duan, Liping Wang, Guoping Feng, Yu Chen, Nancy Y. Ip, James Pickel, Viviana Gradinaru
Journal: Nature Neuroscience (2021)
Ancient Human Genomes and Environmental DNA from the Cement Attaching 2,000-Year-Old Head Lice Nits
Authors: Mikkel W Pedersen, Catia Antunes, Binia De Cahsan, J Víctor Moreno-Mayar, Martin Sikora, Lasse Vinner, Darren Mann, Pavel B Klimov, Stuart Black, Catalina Teresa Michieli, Henk R Braig, M Alejandra Perotti
Journal: Molecular Biology and Evolution (2021)

Over the past few decades, there has been a growing demand for genome analysis of ancient human remains. Destructive sampling is increasingly difficult to obtain for ethical reasons, and standard methods of breaking the skull to access the petrous bone or sampling remaining teeth are often forbidden for curatorial reasons. However, most ancient humans carried head lice and their eggs abound in historical hair specimens. Here we show that host DNA is protected by the cement that glues head lice nits to the hair of ancient Argentinian mummies, 1,500-2,000 years old. The genetic affinities deciphered from genome-wide analyses of this DNA inform that this population migrated from north-west Amazonia to the Andes of central-west Argentina; a result confirmed using the mitochondria of the host lice. The cement preserves ancient environmental DNA of the skin, including the earliest recorded case of Merkel cell polyomavirus. We found that the percentage of human DNA obtained from nit cement equals human DNA obtained from the tooth, yield 2-fold compared with a petrous bone, and 4-fold to a bloodmeal of adult lice a millennium younger. In metric studies of sheaths, the length of the cement negatively correlates with the age of the specimens, whereas hair linear distance between nit and scalp informs about the environmental conditions at the time before death. Ectoparasitic lice sheaths can offer an alternative, nondestructive source of high-quality ancient DNA from a variety of host taxa where bones and teeth are not available and reveal complementary details of their history.
Life Lens
Authors: Kimberly D. Manning
Journal: Annals of Internal Medicine (2021)

Ad LibitumNovember 2021Life LensKimberly D. Manning, MDKimberly D. Manning, MDEmory University Atlanta, GeorgiaSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M21-1967 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Bring your entire self into this spaceYour knotty hair and throaty laughsYour Southern twang and East Coast edgeYour multicolored hijabs and cultural traditionsYour photos from Hanukkah and homemade matzo ball soupYour pierogis, your black-eyed peas, your vegan mac and cheese, and your award-winning hummusOne who stands up ... Author, Article, and Disclosure InformationAffiliations: Emory University Atlanta, GeorgiaCurrent Author Address: Kimberly D. Manning, MD, 49 Jesse Hill Jr. Drive SE, Atlanta, GA 30303; e-mail, [email protected]edu. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics November 2021Volume 174, Issue 11Page: 1635 ePublished: 16 November 2021 Issue Published: November 2021 Copyright & PermissionsCopyright © 2021 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Safety and Efficacy of Combining Tagraxofusp (SL-401) with Azacitidine or Azacitidine and Venetoclax in a Phase 1b Study for CD123 Positive AML, MDS, or BPDCN
Authors: Andrew A. Lane, Anthony S. Stein, Jacqueline S. Garcia, Jada L. Garzon, Ilene Galinsky, Marlise R. Luskin, Richard M. Stone, Eric S. Winer, Rebecca Leonard, Tariq I. Mughal, Christopher L Brooks, Marina Konopleva, Kristen E. Stevenson, Naveen Pemmaraju
Journal: Blood (2021)
Informing the Choice of Direct Oral Anticoagulant Therapy in Patients With Atrial Fibrillation
Authors: Enrico G. Ferro, Dhruv S. Kazi, Peter J. Zimetbaum
Journal: JAMA (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Risk of non-Hodgkin lymphoma in breast cancer survivors: a nationwide cohort study
Authors: Danbee Kang, Sang Eun Yoon, Dongwook Shin, Jin Lee, Yun Soo Hong, Se Kyung Lee, Jeong Eon Lee, Yeon Hee Park, Jin Seok Ahn, Eliseo Guallar, Won Seog Kim, Jungho Lee, Seok Jin Kim, Juhee Cho
Journal: Blood Cancer Journal (2021)
Abstract 12497: Long Transport Distances to a Tertiary Cardiac Arrest Center Does Not Affect Survival in Patients With Out-of-Hospital Cardiac Arrest
Authors: Sivagowry Moerk, Carsten Stengaard, Morten Thingemann Boetker, steffen christensen, Mariann Tang, Christian J Terkelsen
Journal: Circulation (2021)

Introduction: Patients with out-of-hospital cardiac arrest (OHCA) are increasingly transported to tertiary cardiac arrest centers, when the arrest is presumed to be of cardiac origin. For some patients, centralization has led to longer transport distances to advanced care resulting in prolonged prehospital system delays, which may affect outcome. Hypothesis: Longer transport distance to center for patients with OHCA reduces 30-day survival. Methods: Central Denmark Region covers rural and urban areas of 13 000 square kilometers and has a population of approximately 1.3 million inhabitants. Aarhus University Hospital functions as the tertiary cardiac care hospital with access to 24/7 cardiac catherization service and extracorporeal cardiopulmonary resuscitation. Distance to center varies greatly among citizens in the region; with longest distance exceeding 170 km. This observational retrospective study included all patients with OHCA referred to Aarhus University Hospital from 2015 to 2018. Kaplan-Meier curves were conducted to evaluate association between distance and mortality. The odds of 30-day mortality were generated using logistic regression. Results: A total of 807 patients with OHCA were referred to center. Distance to center was &lt; 25km (22%), 25 to 50km (40%), 50 to 100km (20%) and &gt; 100km (18%), respectively. The median prehospital system delay from collapse to arrival at center was 70 minutes [IQR, 55-90 minutes]. Logistic regression did not demonstrate an association between 30-day mortality and increasing distance to center (distance &lt; 25 km as reference, 25 to 50km: OR 0.83, 95% CI [0.58-1.20], 50 to 100km: OR 0.96, 95% CI [0.62-1.47] and &gt;100km: OR 1.20, 95% CI [0.77-1.88]). Conclusions: In OHCA patients with long transport distances to a tertiary cardiac center, survival was similar in patients with short distance to center. Centralization of post cardiac care is feasible in the setting of long transport distances.
Successful endoscopic three-branch self-expandable metallic stent placement using a novel device delivery system for malignant hilar biliary stricture
Authors: Kazuyuki Matsumoto, Hironari Kato, Yuki Fujii, Tatsuhiro Yamazaki, Koichiro Tsutsumi, Shigeru Horiguchi, Hiroyuki Okada
Journal: Endoscopy (2021)

Endoscopic bilateral drainage of high-grade hilar malignant biliary obstruction (HMBO) is technically challenging, even for experienced endoscopists [1]. A novel device delivery system was recently developed, originally intended for placement of a plastic stent in the bile duct. It comprises a slim-tip guide catheter (diameter 1.13 mm) and pusher tube, which facilitate the insertion of devices up to 1.9 mm in diameter [2] [3] [4] [5]. We successfully placed an endoscopic three-branch self-expandable metallic stent (SEMS) using this novel device delivery system with partial stent-in-stent (SIS) for a patient with HMBO.
Table of Contents
Authors: A Chow, K Saini, I Svane, M Juan, F Barlesi, F André, A Menzies, S Lastoria, C Swallow, P Casali, J Blay, N Abecassis, J Bajpai, S Bauer, R Biagini, S Bielack, S Bonvalot, I Boukovinas, J Bovee, K Boye, T Brodowicz, A Buonadonna, E De Álava, A Tos, X Muro, A Dufresne, M Eriksson, A Fedenko, V Ferraresi, A Ferrari, A Frezza, S Gasperoni, H Gelderblom, F Gouin, G Grignani, R Haas, A Hassan, N Hindi, P Hohenberger, H Joensuu, R Jones, C Jungels, P Jutte, B Kasper, A Kawai, K Kopeckova, D Krákorová, A Le Cesne, F Le Grange, E Legius, A Leithner, A Lopez-Pousa, J Martin-Broto, O Merimsky, C Messiou, A Miah, O Mir, M Montemurro, C Morosi, E Palmerini, M Pantaleo, R Piana, S Piperno-Neumann, P Reichardt, P Rutkowski, A Safwat, C Sangalli, M Sbaraglia, S Scheipl, P Schöffski, S Sleijfer, D Strauss, S Strauss, Sundby Hall, A Trama, M Unk, M Van De Sande, W Van Der Graaf, W Van Houdt, T Frebourg, A Gronchi, S Stacchiotti
Journal: Annals of Oncology (2021)